Subcutaneous Teriparatide for Pelvic Fracture Healing: A Phase 2 Randomized Controlled Trial
How to Cite
OrthoEvidence. Subcutaneous Teriparatide for Pelvic Fracture Healing: A Phase 2 Randomized Controlled Trial. ACE Report. 2022;193(1):1. Available from: https://myorthoevidence.com/AceReport/Report/14310
Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial.Osteoporos Int. 2022 Jan;33(1): 239-250.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Thirty-five patients over the age of 50 with an acute pelvic fracture were randomized to receive 3 months of subcutaneous teriparatide injections (n=18) or placebo injections (n=17). Outcomes of interest included pain scores on a Numeric Rating Scale (NRS), physical performance scores (Continuous Summary Physical Performance Score [CSPPS]; timed up and go), and bone healing. Results revealed no si...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE